RenovoRx promotes Leesa Gentry to CCO; salary $325k, option for 190k shares

RenovoRx, Inc.

Leesa Gentry promoted from SVP of Clinical Operations to Chief Clinical Officer, effective March 1, 2024.
Annual base salary of $325,000, with potential increase to $396,000 if CEO salary restored after 2024 reduction.
Eligible for annual discretionary bonus up to 35% of base salary; for 2024 bonus not pro-rated.
Received option to purchase 190,000 shares at $1.69 per share, vesting over 4 years in monthly installments.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Leesa Gentry

Chief Clinical Officer

RNXT · RenovoRx, Inc.

Effective: 2024-03-01
Filed: March 14, 2024, 7:59 PM ET

On February 22, 2024, the board of directors (the “Board”) of RenovoRx, Inc., a Delaware corporation (the “Company”), appointed Leesa Gentry, the Company’s former Senior Vice President of Clinical Operations, to the position of Chief Clinical Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Leesa Gentry was appointed as Chief Clinical Officer at RenovoRx, Inc..

Action: appointed
Role: Chief Clinical Officer

Exact text from the filing

On February 22, 2024, the board of directors (the “Board”) of RenovoRx, Inc., a Delaware corporation (the “Company”), appointed Leesa Gentry, the Company’s former Senior Vice President of Clinical Operations, to the position of Chief Clinical Officer of the Company.

View on SEC.gov

RenovoRx, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-009978

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.